Kaplan Fox Alerts Investors of Unicycive Therapeutics to an Investigation of Possible Securities Law Violations
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are a Unicycive investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571.
On June 10, 2025, before the market opened, Unicycive issued a press release announcing an 'update on its New Drug Application (NDA) for oxlanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.' The press release stated that the U.S. Federal Drug Administration ('FDA') 'communicated to the Company that it had identified deficiencies in cGMP compliance at a third-party manufacturing vendor (one of its CDMO's third-party subcontractors and not its Drug Substance vendor) following an FDA inspection. The FDA indicated that, given the identified deficiencies, any label discussions between the FDA and the Company are precluded. The Company has responded to all FDA information requests and expects a final decision from the FDA by the PDUFA action date of June 28, 2025.'
Following this news, the price of Unicycive stock fell as much as $0.43 per share, over 47%, during intraday trading on June 10, 2025 on unusually heavy volume.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
[email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
[email protected]
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/unicycive-therapeutics-inc/
View the original release on www.newmediawire.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Earnings To Watch: Kinsale Capital Group (KNSL) Reports Q2 Results Tomorrow
Specialty insurance provider Kinsale Capital Group (NYSE:KNSL) will be reporting results this Thursday after the bell. Here's what investors should know. Kinsale Capital Group missed analysts' revenue expectations by 0.7% last quarter, reporting revenues of $423.4 million, up 13.6% year on year. It was a strong quarter for the company, with a solid beat of analysts' book value per share estimates and an impressive beat of analysts' EPS estimates. Is Kinsale Capital Group a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kinsale Capital Group's revenue to grow 12.9% year on year to $434.3 million, slowing from the 30% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.42 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Kinsale Capital Group has missed Wall Street's revenue estimates three times over the last two years. Looking at Kinsale Capital Group's peers in the property & casualty insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Progressive delivered year-on-year revenue growth of 21.3%, beating analysts' expectations by 1.4%, and Travelers reported revenues up 7.3%, in line with consensus estimates. Progressive traded up 2.2% following the results while Travelers was also up 5.5%. Read our full analysis of Progressive's results here and Travelers's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the property & casualty insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.7% on average over the last month. Kinsale Capital Group is up 1.6% during the same time and is heading into earnings with an average analyst price target of $478.38 (compared to the current share price of $485.50). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
26 minutes ago
- Bloomberg
PayPal to Create Global Digital Wallet Platform With Tenpay, UPI
PayPal Holdings Inc. is launching a platform that will enable customers with domestic digital wallets to easily transact with businesses globally, as the payments giant seeks to capture a bigger chunk of the international market. The company's PayPal World platform will allow 'interoperability' between the local digital wallets and PayPal, according to a statement. Its initial partners on the platform include MercadoLibre 's Mercado Pago, National Payments Corporation of India 's UPI and Tencent Holdings ' Tenpay Global, meaning customers with those wallets will be able to send money internationally or shop overseas by clicking on the PayPal button without needing to set up a PayPal account from scratch.
Yahoo
33 minutes ago
- Yahoo
Why JPMorgan says it's getting riskier to hold the market's most popular stocks
JPMorgan is urging investors to use caution when piling into the market's hottest stocks. The bank recently said certain "high beta" stocks are overcrowded. Analysts said there have been several notable instances of crowding in markets this year. With the stock market notching fresh records weekly, it's easy for investors to get excited, but JPMorgan is warning that some of the market's most popular high-growth stocks are looking risky. In a note to clients this week, Dubravko Lakos-Bujas and his team discussed what they described as "extreme crowding episodes" for investors. As they see it, crowding in the market—they flag three notable instances of overcrowding this year—has led to heightened risk, even as stocks continue to rise. The moves, they say, look unsustainable. While the stock market is at records, Lakos-Bujas said that crowding is also nearing record levels, as investors pile into certain high beta stocks. High beta stocks are those that see outsize moves relative to the broader market, offering bigger gains when the market is up but also more pain during declines. The analysts provided a high beta stocks screen with a list of companies with especially high beta scores. Super Micro Computer, a tech stock at the edge of the AI trade with high interest from short sellers, topped the rankings with a beta score of 3.37. Just behind it on JPMorgan's lists are Coinbase Global and Palantir Technologies, two of the tech sector's most popular high-growth stocks. Coinbase has surged recently on momentum from pro-crypto legislation, and Palantir has benefitted from government contracts, as well as enthusiasm for AI. Leading AI chipmakers Nvidia and Broadcom are also among the highest beta stocks. "We believe the current 100%ile crowding based on our quantitative analysis not only presents a risk for this crowded segment, but is also a red flag for the broader market implying there is rising complacency in the short term," the report said. They added that the speed at which the crowding has accelerated is "particularly unsustainable," and marks the fast acceleration in overcrowding in 30 years. "We would fade this rally in High Beta stocks as it is not supported by a bust-to-boom recovery in the business cycle/fundamentals or significant easing in monetary/fiscal policies to sustain this outperformance over multiple quarters." Read the original article on Business Insider Melden Sie sich an, um Ihr Portfolio aufzurufen.
